

IFW

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/559,649  
Applicant : Kandiah JEYASEELAN  
Filed : December 5, 2005  
TC/A.U. : 1754  
Examiner :

Docket No. : 3240-109  
Customer No. : 06449  
Confirmation No. : 5098

INFORMATION DISCLOSURE STATEMENT

Director of the United States Patent  
and Trademark Office  
P.O. Box 1450  
Alexandria, Virginia 22313-1450


Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98,  
Applicant submits herewith information that the Office may wish  
to consider in examination of the subject application. Materials  
submitted for consideration are listed on the attached form PTO-  
1449.

Respectfully submitted,

By Barbara G. Ernst  
Barbara G. Ernst  
Attorney for Applicants  
Registration No. 30,377  
ROTHWELL, FIGG, ERNST & MANBECK, p.c.  
Suite 800, 1425 K Street, N.W.  
Washington, D.C. 20005  
Telephone: (202) 783-6040

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**



*Complete if Known*

Application Number	10/559,649
Filing Date	December 5, 2005
First Named Inventor	Kandiah JEYASEELAN
Group Art Unit	1754
Examiner Name	
Confirmation No.	5098

Sheet

1

of

4

Attorney Docket Number 3240-109

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
	AA	5,622,985		Olukotun et al.	04-22-1997
	AB	5,674,893		Behounek et al.	10-07-1997
	AC	5,902,805		Breton et al.	05-11-1999

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code.


<sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.



## FOREIGN PATENT DOCUMENTS

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**



Complete if Known

<p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p>				Application Number	10/559,649
				Filing Date	December 5, 2005
				First Named Inventor	Kandiah JEYASEELAN
				Group Art Unit	1754
				Examiner Name	
				Confirmation No.	5098
Sheet	3	of	4	Attorney Docket Number	3240-109

**NON PATENT LITERATURE DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AE	BROWN, M.S., et al., "Scavenger cell receptor shared," <i>Nature</i> , August 22, 1985, pp. 680-681, Vol. 316.	
	AF	BROWN, M.S., et al., "A Receptor-Mediated Pathway for Cholesterol Homeostasis," <i>Science</i> , April 4, 1986, pp. 34-47, Vol. 23.	
	AG	BROWN, W.V., et al., "Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial," <i>American Heart Journal</i> , December 2002, pp. 1036-1043, Vol. 144, No. 6.	
	AH	COHEN, L.H. et al., "Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes," <i>Biopharm Drug Dispos</i> , Dec. 2000, pp. 353-364, vol. 21, no. 9. (Abstract)	AB
	AI	ENDO, A., et al., "Competitive Inhibition of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase by ML-236A and ML-236B Fungal Metabolites, Having Hypocholesterolemic Activity," <i>FEBS Letters</i> , December 1976, pp. 323-326, vol. 72, no. 2.	
	AJ	FELESZKO, W., et al., "Lovastatin and Tumor Necrosis Factor- $\alpha$ Exhibit Potentiated Antitumor Effects Against Ha-ras-Transformed Murine Tumor Via Inhibition of Tumor-Induced Angiogenesis," <i>Int. J. Cancer</i> , 1999, pp. 560-567, vol. 81. Wiley-Liss, Inc.	
	AK	JONES, M.K., et al., "Activation of VEGF and Ras Genes In gastric mucosa during angiogenic response to ethanol injury," <i>Am. J. Physiol.</i> , 1999, pp. G-1345-G1355, vol. 276.	
	AL	KONG, D., et al., "The Anti-Angiogenic Effects of HMGCoA Reductase Inhibitors: A New Role for RhoA GTPase in the Regulation of Angiogenesis," <i>Circulation</i> , 1999, pp. 1-39, vol. 100, no. 18. Abstract #194.	AB
	AM	LIAO, J.K., "Isoprenoids as mediators of the biological effects of statins," <i>J. Clin. Invest.</i> , August 2002, pp. 285-288, vol. 110, no. 3.	
	AN	NEZASA, K., et al., "Liver-Specific Distribution Of Rosuvastatin In Rats: Comparison With Pravastatin And Simvastatin," <i>Drug Metab Dispos</i> , 2002, pp. 1158-1163, vol. 30, no. 11. The American Society for Pharmacology and Experimental Therapeutics.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**



Complete if Known

Application Number	10/559,649
Filing Date	December 5, 2005
First Named Inventor	Kandish JEYASEELAN
Group Art Unit	1754
Examiner Name	
Confirmation No.	5098
Attorney Docket Number	3240-109

Sheet

4

of

4

AO	SERAJUDDIN, A.T.M., et al., "Relative Lipophilicities, Solubilities, and Structure-Pharmacological Considerations of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors Pravastatin, Lovastatin, Mevastatin, and Simvastatin," <i>J. Pharm. Sci.</i> , 1991, pp. 830-834, vol. 80, no. 9.	
AP	TAKEMOTO, M., et al., "Pleiotropic Effects Of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors," <i>Arterioscler. Thromb. Vasc. Biol.</i> , 2001, pp. 1712-1719, vol. 21, no. 11. American Heart Association.	
AQ	VAUGHAN, C.J., "Prevention of Stroke and Dementia with Statins: Effects Beyond Lipid Lowering," <i>Am. J. Cardiol.</i> , February 20, 2003, pp. 23B-29B, vol. 91 (suppl), no. 4A. Excerpta Medica, Inc.	
Examiner Signature		Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.